-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that the GLR1075 injection independently developed by the company is undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject.

Zhitongcaijing·10/12/2026 09:57:06
Listen to the news
Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that the GLR1075 injection independently developed by the company is undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject.